Acetate production

Acetate production estimates the genetic potential of your gut microbes to make acetate. The result comes from sequencing microbial DNA in stool and identifying genes involved in that process. It describes a microbial capability. It is not the amount of acetate in your stool or the rate at which your bacteria produce it.

This is an exploratory microbiome marker. Its value for choosing treatments or predicting disease has not been established, and there is no validated target to optimize.

What the Number Represents

The analysis identifies microbial genes and groups them into biological functions. A greater representation of acetate-making genes supports greater genetic potential for that function. Actual output also depends on which genes are active, what nutrients are available, and how microbes interact.

A relative abundance or percentile describes your sample within an analysis or comparison group. It cannot be converted into an acetate concentration, a daily production rate, or the percentage of dietary fiber you ferment. A percentile also isn't a probability of disease.

How Acetate Fits Into Gut Fermentation

Acetate is a short-chain fatty acid made by many gut bacteria when they ferment carbohydrates that reach the colon. Some bacteria also build it from hydrogen and carbon dioxide or from formate. Your body absorbs and uses acetate, while some gut bacteria take it up to make butyrate.

That exchange has been demonstrated in people. In a study of 12 healthy adults, researchers delivered labelled acetate into the colon and estimated that about a quarter (24%) was converted into butyrate, the most common conversion they observed. About a third of the acetate reached the bloodstream. This was a tracer experiment measuring metabolism, so its findings explain the biology without validating a stool DNA production score.

A direct stool acetate measurement captures the concentration remaining after microbial production, microbial use, absorption, and movement through the bowel. More than 95% of the short-chain fatty acids made in the colon are absorbed, so stool levels may say more about absorption than about production. Blood acetate reflects another compartment. These measurements describe different parts of the process and can change independently.

What Human Disease Studies Show

Most of the disease research cited for acetate measured the chemical itself in stool or blood. Those findings cannot be applied directly to a DNA-based production score. For example, a study of 441 adults associated higher fecal short-chain fatty acid concentrations with gut dysbiosis, greater gut permeability, obesity, hypertension, and other metabolic findings. The authors proposed less efficient absorption as one explanation, so a high stool level there may reflect what the colon failed to take up rather than greater production. The study did not establish that a higher acetate production score predicts those conditions.

Studies comparing people with colorectal cancer against healthy controls have often found lower fecal acetate concentrations, though results vary. A 2025 meta-analysis pooled only four studies, and the difference for butyrate was larger than the difference for acetate. Its authors concluded that fecal fatty acid profiling is not yet standardized enough for clinical use. These are associations in people who already have disease. They don't establish that low microbial production potential predicts future cancer.

The distinction matters for inflammatory bowel disease too. A study measuring fecal short-chain fatty acids found that they could not distinguish Crohn's disease from ulcerative colitis or reliably predict disease severity. In ulcerative colitis, fecal acetate and butyrate did track with inflammation markers such as calprotectin and C-reactive protein, but that did not make them useful diagnostic tests. A later study reported fatty acid ratios that separated the two conditions, without confirming the result in a separate group of patients. Neither the chemical measurement nor this production score replaces established investigations for intestinal inflammation.

When Results Can Be Misleading

• Genetic potential and current activity differ: finding a gene does not establish how actively it is being used. A production score cannot establish how much acetate reaches your blood or how well your colon absorbs it.
• Relative results depend on the rest of the sample: a function's relative abundance can rise because other functions become less abundant. That does not necessarily mean more acetate-making genes or organisms are present in absolute terms.
• Methods affect the number: DNA extraction, sequencing depth, reference databases, and computational analysis can change which genes are detected and how their abundance is reported. Results from different methods or laboratories are not directly interchangeable.
• Diet, medicines, and illness change the microbial community: recent antibiotics, dietary changes, bowel preparation, or a gastrointestinal infection can make a sample less representative of your usual state.
• Collection and storage affect the DNA profile: contamination, unsuitable preservation, and departures from the kit's handling instructions can alter the result. Acetate's volatility is a concern for chemical measurements, not the main explanation for error in a microbial DNA analysis.

A study comparing commercial microbiome services found substantial differences when they analyzed the same standardized stool material. It evaluated microbial profiles, not this acetate score specifically, but supports caution when comparing results across providers.

Understanding Changes Over Time

Your microbial community can change, so this result can change too. A repeated measurement may describe a shift in genetic potential, but an upward or downward trend has no established meaning as a health improvement. Your previous result is a comparison point, not a personal healthy target.